药品详细
Alprenolol(心安)
化学结构式图
中文名
心安
英文名
Alprenolol
分子式
C15H23NO2
化学名
{2-hydroxy-3-[2-(prop-2-en-1-yl)phenoxy]propyl}(propan-2-yl)amine
分子量
Average: 249.3486
Monoisotopic: 249.172878985
Monoisotopic: 249.172878985
CAS号
13655-52-2
ATC分类
C07A 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. [PubChem]
生产厂家
封装厂家
参考
Synthesis Reference | Not Available |
General Reference | Not Available |
剂型
规格
化合物类型
Type | small molecule |
Classes |
|
Substructures |
|
适应症
药理
Indication | For the treatment of hypertension, angina, and arrhythmia | ||||||||
Pharmacodynamics | Alprenolol is a non-selective beta-blocker used in the treatment of hypertension, edema, ventricular tachycardias, and atrial fibrillation. Alprenolol impairs AV node conduction and decreases sinus rate and may also increase plasma triglycerides and decrease HDL-cholesterol levels. Alprenolol is nonpolar and hydrophobic, with low to moderate lipid solubility. Alprenolol has little to no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, alprenolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action. | ||||||||
Mechanism of action | Alprenolol non-selectively blocks beta-1 adrenergic receptors mainly in the heart, inhibiting the effects of epinephrine and norepinephrine resulting in a decrease in heart rate and blood pressure. Also, with a more minor effect, by binding beta-2 receptors in the juxtaglomerular apparatus, alprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. | ||||||||
Absorption | Not Available | ||||||||
Volume of distribution | Not Available | ||||||||
Protein binding | 80-90% | ||||||||
Metabolism |
Hepatic. One of the active metabolites, 4-OH-alprenolol, is an active beta-blocker.
Important The metabolism module of DrugBank is currently in beta. Questions or suggestions? Please contact us.
|
||||||||
Route of elimination | Not Available | ||||||||
Half life | 2-3 hours | ||||||||
Clearance | Not Available | ||||||||
Toxicity | LD50=597.0 mg/kg (Orally in rats) | ||||||||
Affected organisms |
|
||||||||
Pathways |
|
理化性质
Properties | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
State | solid | ||||||||||||||||||||||||||||||||||||||||||
Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
Predicted Properties |
|
药物相互作用
食物相互作用
Not Available